ANALISIS PENGHEMATAN BIAYA OBAT MELALUI SUBSTITUSI GENERIK PADA KARYAWAN PT KORINDO ARIABIMA SARI DI KOTAWARINGIN BARAT
Background: The problem on health financing always becomes an issue that may alienate the public from health care centers. Drug costs take a significant proportion and may be an intervention tool to improve health status. Efforts to make drug-cost savings by private companies have often been made. H...
| Main Authors: | , |
|---|---|
| Format: | Thesis |
| Published: |
[Yogyakarta] : Universitas Gadjah Mada
2013
|
| Subjects: |
| _version_ | 1826047081403383808 |
|---|---|
| author | , MIA ANDRIYANI , Prof. Dr. Dra. Sri Suryawati, Apt. |
| author_facet | , MIA ANDRIYANI , Prof. Dr. Dra. Sri Suryawati, Apt. |
| author_sort | , MIA ANDRIYANI |
| collection | UGM |
| description | Background: The problem on health financing always becomes an issue that may
alienate the public from health care centers. Drug costs take a significant
proportion and may be an intervention tool to improve health status. Efforts to
make drug-cost savings by private companies have often been made. However,
there are not many data that can be disclosed. Drug-cost savings made to control
health funding by the private companies can be done by the selection of drugs
through generic substitution.
Methods: This is a case study using descriptive analysis. The quantitative data
were collected from the prescribing of the company�s outpatient employees within
January 2013 - March 2013. The qualitative data were collected by conducted indepth
interviews to reveal the opinions of the key stakeholders to the private
companies, the doctor prescribers, and the pharmacists managing pharmacies
about the generic substitution which had been done.
Research findings: The findings of this research indicated the presence of drugcost
savings before and after the generic substitution was implemented by 19%
towards 1179 prescription sheets with the number of R/ as many as 3476. The
number of R / written using the generic name was 23%, the number of R /
substituted was 21%, and the number of R / not substituted was 56%. The
opportunity for further savings can be improved through the drugs which have not
been substituted and through the drug substitution following the therapy groups of
anti-infective drugs (32%) and cardiovascular drugs (13%). This substitution
policy is considered important by the company because it can reduce drug
financing spent on the implementation of the employee health system.
Conclusions: Drug-cost savings made by PT Korindo Ariabima Sari is considered
important since the savings could reduce drug financing by Rp16.332.300, - or
19%, with the average number of R/ prescription sheet was 3 and the percentage
of the drugs handed over using the generic name was 23% and the percentage of
the patients receiving vitamin and supplement prescriptions was 7% without
decreasing the quality of the services from the doctors. |
| first_indexed | 2024-03-13T23:04:34Z |
| format | Thesis |
| id | oai:generic.eprints.org:123712 |
| institution | Universiti Gadjah Mada |
| last_indexed | 2024-03-13T23:04:34Z |
| publishDate | 2013 |
| publisher | [Yogyakarta] : Universitas Gadjah Mada |
| record_format | dspace |
| spelling | oai:generic.eprints.org:1237122016-03-04T08:40:18Z https://repository.ugm.ac.id/123712/ ANALISIS PENGHEMATAN BIAYA OBAT MELALUI SUBSTITUSI GENERIK PADA KARYAWAN PT KORINDO ARIABIMA SARI DI KOTAWARINGIN BARAT , MIA ANDRIYANI , Prof. Dr. Dra. Sri Suryawati, Apt. ETD Background: The problem on health financing always becomes an issue that may alienate the public from health care centers. Drug costs take a significant proportion and may be an intervention tool to improve health status. Efforts to make drug-cost savings by private companies have often been made. However, there are not many data that can be disclosed. Drug-cost savings made to control health funding by the private companies can be done by the selection of drugs through generic substitution. Methods: This is a case study using descriptive analysis. The quantitative data were collected from the prescribing of the company�s outpatient employees within January 2013 - March 2013. The qualitative data were collected by conducted indepth interviews to reveal the opinions of the key stakeholders to the private companies, the doctor prescribers, and the pharmacists managing pharmacies about the generic substitution which had been done. Research findings: The findings of this research indicated the presence of drugcost savings before and after the generic substitution was implemented by 19% towards 1179 prescription sheets with the number of R/ as many as 3476. The number of R / written using the generic name was 23%, the number of R / substituted was 21%, and the number of R / not substituted was 56%. The opportunity for further savings can be improved through the drugs which have not been substituted and through the drug substitution following the therapy groups of anti-infective drugs (32%) and cardiovascular drugs (13%). This substitution policy is considered important by the company because it can reduce drug financing spent on the implementation of the employee health system. Conclusions: Drug-cost savings made by PT Korindo Ariabima Sari is considered important since the savings could reduce drug financing by Rp16.332.300, - or 19%, with the average number of R/ prescription sheet was 3 and the percentage of the drugs handed over using the generic name was 23% and the percentage of the patients receiving vitamin and supplement prescriptions was 7% without decreasing the quality of the services from the doctors. [Yogyakarta] : Universitas Gadjah Mada 2013 Thesis NonPeerReviewed , MIA ANDRIYANI and , Prof. Dr. Dra. Sri Suryawati, Apt. (2013) ANALISIS PENGHEMATAN BIAYA OBAT MELALUI SUBSTITUSI GENERIK PADA KARYAWAN PT KORINDO ARIABIMA SARI DI KOTAWARINGIN BARAT. UNSPECIFIED thesis, UNSPECIFIED. http://etd.ugm.ac.id/index.php?mod=penelitian_detail&sub=PenelitianDetail&act=view&typ=html&buku_id=63826 |
| spellingShingle | ETD , MIA ANDRIYANI , Prof. Dr. Dra. Sri Suryawati, Apt. ANALISIS PENGHEMATAN BIAYA OBAT MELALUI SUBSTITUSI GENERIK PADA KARYAWAN PT KORINDO ARIABIMA SARI DI KOTAWARINGIN BARAT |
| title | ANALISIS PENGHEMATAN BIAYA OBAT MELALUI SUBSTITUSI GENERIK PADA KARYAWAN PT KORINDO ARIABIMA SARI DI KOTAWARINGIN BARAT |
| title_full | ANALISIS PENGHEMATAN BIAYA OBAT MELALUI SUBSTITUSI GENERIK PADA KARYAWAN PT KORINDO ARIABIMA SARI DI KOTAWARINGIN BARAT |
| title_fullStr | ANALISIS PENGHEMATAN BIAYA OBAT MELALUI SUBSTITUSI GENERIK PADA KARYAWAN PT KORINDO ARIABIMA SARI DI KOTAWARINGIN BARAT |
| title_full_unstemmed | ANALISIS PENGHEMATAN BIAYA OBAT MELALUI SUBSTITUSI GENERIK PADA KARYAWAN PT KORINDO ARIABIMA SARI DI KOTAWARINGIN BARAT |
| title_short | ANALISIS PENGHEMATAN BIAYA OBAT MELALUI SUBSTITUSI GENERIK PADA KARYAWAN PT KORINDO ARIABIMA SARI DI KOTAWARINGIN BARAT |
| title_sort | analisis penghematan biaya obat melalui substitusi generik pada karyawan pt korindo ariabima sari di kotawaringin barat |
| topic | ETD |
| work_keys_str_mv | AT miaandriyani analisispenghematanbiayaobatmelaluisubstitusigenerikpadakaryawanptkorindoariabimasaridikotawaringinbarat AT profdrdrasrisuryawatiapt analisispenghematanbiayaobatmelaluisubstitusigenerikpadakaryawanptkorindoariabimasaridikotawaringinbarat |